These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 121849)

  • 41. [Re-evaluation of anti-Hansenian chemotherapy by long-term study and by experimental and pharmacokinetic criteria].
    Carayon A
    Acta Leprol; 1980; (79):55-65. PubMed ID: 6794334
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapeutic effect of rifampicin (RFP) on leprosy. I. Clinical effect (observation of twelve months) (author's transl)].
    Repura; 1974; 43(1):8-25. PubMed ID: 4479678
    [No Abstract]   [Full Text] [Related]  

  • 43. [Result of studies of immunotherapy of lepromatous leprosy and borderline leprosy].
    Saint-André P; Baquillon G; Ferracci C; Ridel PR
    Acta Leprol; 1981; (84):39-55. PubMed ID: 6797222
    [No Abstract]   [Full Text] [Related]  

  • 44. Further observations on streptomycin combined with sulfones in relapsed lepromatous leprosy.
    Hastings RC; Trautman JR; Mansfield RE
    Int J Lepr Other Mycobact Dis; 1969; 37(2):130-4. PubMed ID: 5389014
    [No Abstract]   [Full Text] [Related]  

  • 45. [Inadequate rifampicin treatment in multibacillary leprosy and the incubation time of relapse].
    Pattyn SR; Husser JA; Baquillon G; Grillone S; Van Loo G; Bourland J
    Acta Leprol; 1986; 4(3):301-2. PubMed ID: 3551469
    [No Abstract]   [Full Text] [Related]  

  • 46. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Length of continued treatment of an inactive case of leprosy.
    Dharmendra
    Lepr India; 1976 Jul; 48(3):212-6. PubMed ID: 1022967
    [No Abstract]   [Full Text] [Related]  

  • 48. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
    Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
    Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of two multidrug regimens in multibacillary leprosy.
    Jadhav VH; Patki AH; Mehta JM
    Indian J Lepr; 1992; 64(4):501-4. PubMed ID: 1308526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [How should leprosy be treated?].
    Mahé A
    Ann Dermatol Venereol; 1998 Dec; 125(12):881-3. PubMed ID: 9922859
    [No Abstract]   [Full Text] [Related]  

  • 51. [In vitro immunologic changes in 6 lepromatous leprosy or borderline leprosy patients treated with BCG alone or BCG and lepromin for 12 to 20 months, followed by BCG and antibiochemotherapy for 1 to 2 years].
    Saint-André P; Ferracci C; Baquillon G; Travi Piacentile M
    Acta Leprol; 1979; (76-77):311-4. PubMed ID: 121851
    [No Abstract]   [Full Text] [Related]  

  • 52. Persister M. leprae after introductory rifampicin followed by dapsone therapy.
    Sreevatsa ; Girdhar BK; Desikan KV
    Lepr India; 1981 Jul; 53(3):350-3. PubMed ID: 7278139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bacteriologic study in patients with multibacillary leprosy treated with rifampicin and acedapsone].
    Olivares Sabournin R; González Segredo AB
    Rev Cubana Med Trop; 1989; 41(2):307-12. PubMed ID: 2486227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment of leprosy with the sulfones. I. Faget's original 22 patients. A thirty-year follow-up on sulfone therapy for leprosy.
    Jacobson RR; Trautman JR
    Int J Lepr Other Mycobact Dis; 1971; 39(3):726-37. PubMed ID: 4948221
    [No Abstract]   [Full Text] [Related]  

  • 55. Multiple cold abscesses in a borderline lepromatous patient on multidrug therapy.
    Kulkarni V; Gharpuray MB; Kulkarni DS
    Indian J Lepr; 1989 Oct; 61(4):442-4. PubMed ID: 2621380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immunomorphology of lepromatous leprosy].
    Kop'eva TN
    Arkh Patol; 1972; 34(4):35-41. PubMed ID: 5043685
    [No Abstract]   [Full Text] [Related]  

  • 57. [Tuberculoid leprosy treated with rifampicin].
    Guilaine J; Stérin D; Després E; Lesobre R
    Bull Soc Fr Dermatol Syphiligr; 1969; 76(6):749-50. PubMed ID: 5384187
    [No Abstract]   [Full Text] [Related]  

  • 58. [Therapeutic effect of rifampicin (RFP) on leprosy. II. On the changes of the morphological index of M. leprae in patients (author's transl)].
    Ozawa T
    Repura; 1974; 43(1):26-34. PubMed ID: 4610308
    [No Abstract]   [Full Text] [Related]  

  • 59. [Immunologic and histomorphologic features of responsiveness in patients with leprosy at different stages of treatment].
    Strukov AI; Babaiants RS; Shakhtmeĭster IIa; Kopieva TN; Goloschapov NM
    Vestn Dermatol Venerol; 1972 Oct; 46(10):8-12. PubMed ID: 4569353
    [No Abstract]   [Full Text] [Related]  

  • 60. Complement-fixing antibodies in the sera of 534 lepromatous lepers under treatment with sulfones.
    DE ALMEIDA JO; CARVALHO RP; PADRON C
    Rev Bras Leprol; 1956 Sep; 24(3):123-32. PubMed ID: 13420747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.